Risk for Type 1 Diabetes
Conditions
Brief summary
The primary efficacy outcome is the elapsed time from random treatment assignment to the development of persistent confirmed islet autoantibod-ies or type 1 diabetes
Detailed description
The elapsed time from random treatment assignment to the development of per-sistent confirmed multiple islet autoan-tibodies; the development of type 1 diabetes; the development of persistent con-firmed transglutaminase autoantibodies
Interventions
DRUGComirnaty Omicron XBB.1.5 3 micrograms/dose concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified)
DRUG0.9% Sodium Chloride solution for injection (saline)
Sponsors
Klinikum rechts der Isar der TU Muenchen AöR
Eligibility
Sex/Gender
All
Age
0 Years to 17 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary efficacy outcome is the elapsed time from random treatment assignment to the development of persistent confirmed islet autoantibod-ies or type 1 diabetes | — |
Secondary
| Measure | Time frame |
|---|---|
| The elapsed time from random treatment assignment to the development of per-sistent confirmed multiple islet autoan-tibodies; the development of type 1 diabetes; the development of persistent con-firmed transglutaminase autoantibodies | — |
Countries
Austria, Belgium, Germany, Italy, Poland, Sweden
Outcome results
None listed